DUBLIN and BERWYN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- We are proud to announce that AscellaHealth has been awarded Gold ...

A first-in-class, brain-penetrant sGC stimulator, zagociguat is hypothesized to rebalance dysregulated cellular pathways in MELAS. By restoring cellular functions that support mitochondria, zagociguat ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today congratulates its ...

AST-004 is the first drug to show the ability in preclinical studies to protect the brain from the harmful effects of both mild and severe brain injuries. It is designed to preserve and protect brain ...

Geopolitical instability and the ongoing trade dispute with the United States have emerged as a major financial concern for Canadians and is having an impact on people’s retirement planning, according ...

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty ...

The webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event.

Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today announced a series of corporate updates following the closing of all its previously-announced definitive merger agreements ...

Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that it is attending and presenting at the 2nd Asia Pacific Conference ...

Llusern Scientific, a point-of-care diagnostics company, announces it has been awarded ISO 13485 certification for its Lodestar DX testing system, a rapid molecular diagnostic platform for urinary ...

Over the next five years, the study will screen more than two million individuals, integrating gut microbiome, metabolomics, lipidomics, proteomics, exposomics, and wearable biosensor data to deliver ...

Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the development of next-generation antibody-drug conjugates ...